Victoza reduces CV risk in type 2 diabetes regardless of severe hypoglycemia events

12 June 2017

Findings from a post-hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that the Novo Nordisk (NOV: N) treatment Victoza (liraglutide) resulted in similar reductions in the chance of major CV events in people with type 2 diabetes at high CV risk, regardless of whether they experienced an episode of severe hypoglycemia during the study.

The results were presented by the Danish pharma company late on Monday at the American Diabetes Association 77th Scientific Sessions.

For the overall LEADER population, regardless of treatment group, people who experienced a severe hypoglycemic episode were at a significantly greater risk of major cardiovascular adverse events (CV death, non-fatal heart attack or non-fatal stroke), CV-death or non-CV death.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK